FIGURE

Fig. S12

ID

ZDB-FIG-130907-43

Publication

McCarthy et al., 2013 - Pdgfra protects against ethanol-induced craniofacial defects in a zebrafish model of FASD

Other Figures

All Figure Page

Back to All Figure Page

Fig. S12

Both wortmannin- and rapamycin-treated pdgfra mutants show a decrease in overall neurocranial length and width. (A-C) Embryos were treated from 10-24 hpf with either DMSO, 1.0% ethanol, 1.5 μM wortmannin or 3 μM rapamycin. Inhibition of either PI3K or mTOR phenocopies the effects of ethanol. Graphs depict the average (A) palate length, (B) posterior neurocranial length and (C) neurocranial width in μm (standard error bars are 1.5 s.e.m., non-overlapping bars indicate significance; Moses, 1987). Wild-type, light bar; pdgfra heterozygote, light-gray bar; mutant, dark-gray bar. (D) An Alcian Blue- and Alizarin Red-stained 5 dpf untreated wild-type neurocranium. Palate length was measured from the most anterior part of the ethmoid plate (ep) to the ends of the trabeculae (tr). The posterior neurocranium was measured from the most posterior part of the occipital arches (oc) to the ends of the trabeculae (tr). Neurocranial width was measured between the most lateral edges of the lateral commissures (lc). D, DMSO; E, ethanol; W, wortmannin, R, rapamycin.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Development